Role of cyclooxygenase-2-mediated prostaglandin E2-prostaglandin E receptor 4 signaling in cardiac reprogramming

Naoto Muraoka, Kaori Nara, Fumiya Tamura, Hidenori Kojima, Hiroyuki Yamakawa, Taketaro Sadahiro, Kazutaka Miyamoto, Mari Isomi, Sho Haginiwa, Hidenori Tani, Shota Kurotsu, Rina Osakabe, Satoru Torii, Shigeomi Shimizu, Hideyuki Okano, Yukihiko Sugimoto, Keiichi Fukuda, Masaki Ieda

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Direct cardiac reprogramming from fibroblasts can be a promising approach for disease modeling, drug screening, and cardiac regeneration in pediatric and adult patients. However, postnatal and adult fibroblasts are less efficient for reprogramming compared with embryonic fibroblasts, and barriers to cardiac reprogramming associated with aging remain undetermined. In this study, we screened 8400 chemical compounds and found that diclofenac sodium (diclofenac), a non-steroidal anti-inflammatory drug, greatly enhanced cardiac reprogramming in combination with Gata4, Mef2c, and Tbx5 (GMT) or GMT plus Hand2. Intriguingly, diclofenac promoted cardiac reprogramming in mouse postnatal and adult tail-tip fibroblasts (TTFs), but not in mouse embryonic fibroblasts (MEFs). Mechanistically, diclofenac enhanced cardiac reprogramming by inhibiting cyclooxygenase-2, prostaglandin E2/prostaglandin E receptor 4, cyclic AMP/protein kinase A, and interleukin 1β signaling and by silencing inflammatory and fibroblast programs, which were activated in postnatal and adult TTFs. Thus, anti-inflammation represents a new target for cardiac reprogramming associated with aging.

Original languageEnglish
Article number674
JournalNature communications
Volume10
Issue number1
DOIs
Publication statusPublished - 2019 Dec 1

Fingerprint

Receptors, Prostaglandin E, EP4 Subtype
prostaglandins
fibroblasts
Cyclooxygenase 2
Fibroblasts
Dinoprostone
Diclofenac
mice
Tail
drugs
cyclic AMP
Aging of materials
interleukins
Adenylate Kinase
chemical compounds
Preclinical Drug Evaluations
Pediatrics
Chemical compounds
Cyclic AMP-Dependent Protein Kinases
regeneration

ASJC Scopus subject areas

  • Chemistry(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Physics and Astronomy(all)

Cite this

Role of cyclooxygenase-2-mediated prostaglandin E2-prostaglandin E receptor 4 signaling in cardiac reprogramming. / Muraoka, Naoto; Nara, Kaori; Tamura, Fumiya; Kojima, Hidenori; Yamakawa, Hiroyuki; Sadahiro, Taketaro; Miyamoto, Kazutaka; Isomi, Mari; Haginiwa, Sho; Tani, Hidenori; Kurotsu, Shota; Osakabe, Rina; Torii, Satoru; Shimizu, Shigeomi; Okano, Hideyuki; Sugimoto, Yukihiko; Fukuda, Keiichi; Ieda, Masaki.

In: Nature communications, Vol. 10, No. 1, 674, 01.12.2019.

Research output: Contribution to journalArticle

Muraoka, N, Nara, K, Tamura, F, Kojima, H, Yamakawa, H, Sadahiro, T, Miyamoto, K, Isomi, M, Haginiwa, S, Tani, H, Kurotsu, S, Osakabe, R, Torii, S, Shimizu, S, Okano, H, Sugimoto, Y, Fukuda, K & Ieda, M 2019, 'Role of cyclooxygenase-2-mediated prostaglandin E2-prostaglandin E receptor 4 signaling in cardiac reprogramming', Nature communications, vol. 10, no. 1, 674. https://doi.org/10.1038/s41467-019-08626-y
Muraoka, Naoto ; Nara, Kaori ; Tamura, Fumiya ; Kojima, Hidenori ; Yamakawa, Hiroyuki ; Sadahiro, Taketaro ; Miyamoto, Kazutaka ; Isomi, Mari ; Haginiwa, Sho ; Tani, Hidenori ; Kurotsu, Shota ; Osakabe, Rina ; Torii, Satoru ; Shimizu, Shigeomi ; Okano, Hideyuki ; Sugimoto, Yukihiko ; Fukuda, Keiichi ; Ieda, Masaki. / Role of cyclooxygenase-2-mediated prostaglandin E2-prostaglandin E receptor 4 signaling in cardiac reprogramming. In: Nature communications. 2019 ; Vol. 10, No. 1.
@article{49023029b6be4967956fb505a755a91f,
title = "Role of cyclooxygenase-2-mediated prostaglandin E2-prostaglandin E receptor 4 signaling in cardiac reprogramming",
abstract = "Direct cardiac reprogramming from fibroblasts can be a promising approach for disease modeling, drug screening, and cardiac regeneration in pediatric and adult patients. However, postnatal and adult fibroblasts are less efficient for reprogramming compared with embryonic fibroblasts, and barriers to cardiac reprogramming associated with aging remain undetermined. In this study, we screened 8400 chemical compounds and found that diclofenac sodium (diclofenac), a non-steroidal anti-inflammatory drug, greatly enhanced cardiac reprogramming in combination with Gata4, Mef2c, and Tbx5 (GMT) or GMT plus Hand2. Intriguingly, diclofenac promoted cardiac reprogramming in mouse postnatal and adult tail-tip fibroblasts (TTFs), but not in mouse embryonic fibroblasts (MEFs). Mechanistically, diclofenac enhanced cardiac reprogramming by inhibiting cyclooxygenase-2, prostaglandin E2/prostaglandin E receptor 4, cyclic AMP/protein kinase A, and interleukin 1β signaling and by silencing inflammatory and fibroblast programs, which were activated in postnatal and adult TTFs. Thus, anti-inflammation represents a new target for cardiac reprogramming associated with aging.",
author = "Naoto Muraoka and Kaori Nara and Fumiya Tamura and Hidenori Kojima and Hiroyuki Yamakawa and Taketaro Sadahiro and Kazutaka Miyamoto and Mari Isomi and Sho Haginiwa and Hidenori Tani and Shota Kurotsu and Rina Osakabe and Satoru Torii and Shigeomi Shimizu and Hideyuki Okano and Yukihiko Sugimoto and Keiichi Fukuda and Masaki Ieda",
year = "2019",
month = "12",
day = "1",
doi = "10.1038/s41467-019-08626-y",
language = "English",
volume = "10",
journal = "Nature Communications",
issn = "2041-1723",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Role of cyclooxygenase-2-mediated prostaglandin E2-prostaglandin E receptor 4 signaling in cardiac reprogramming

AU - Muraoka, Naoto

AU - Nara, Kaori

AU - Tamura, Fumiya

AU - Kojima, Hidenori

AU - Yamakawa, Hiroyuki

AU - Sadahiro, Taketaro

AU - Miyamoto, Kazutaka

AU - Isomi, Mari

AU - Haginiwa, Sho

AU - Tani, Hidenori

AU - Kurotsu, Shota

AU - Osakabe, Rina

AU - Torii, Satoru

AU - Shimizu, Shigeomi

AU - Okano, Hideyuki

AU - Sugimoto, Yukihiko

AU - Fukuda, Keiichi

AU - Ieda, Masaki

PY - 2019/12/1

Y1 - 2019/12/1

N2 - Direct cardiac reprogramming from fibroblasts can be a promising approach for disease modeling, drug screening, and cardiac regeneration in pediatric and adult patients. However, postnatal and adult fibroblasts are less efficient for reprogramming compared with embryonic fibroblasts, and barriers to cardiac reprogramming associated with aging remain undetermined. In this study, we screened 8400 chemical compounds and found that diclofenac sodium (diclofenac), a non-steroidal anti-inflammatory drug, greatly enhanced cardiac reprogramming in combination with Gata4, Mef2c, and Tbx5 (GMT) or GMT plus Hand2. Intriguingly, diclofenac promoted cardiac reprogramming in mouse postnatal and adult tail-tip fibroblasts (TTFs), but not in mouse embryonic fibroblasts (MEFs). Mechanistically, diclofenac enhanced cardiac reprogramming by inhibiting cyclooxygenase-2, prostaglandin E2/prostaglandin E receptor 4, cyclic AMP/protein kinase A, and interleukin 1β signaling and by silencing inflammatory and fibroblast programs, which were activated in postnatal and adult TTFs. Thus, anti-inflammation represents a new target for cardiac reprogramming associated with aging.

AB - Direct cardiac reprogramming from fibroblasts can be a promising approach for disease modeling, drug screening, and cardiac regeneration in pediatric and adult patients. However, postnatal and adult fibroblasts are less efficient for reprogramming compared with embryonic fibroblasts, and barriers to cardiac reprogramming associated with aging remain undetermined. In this study, we screened 8400 chemical compounds and found that diclofenac sodium (diclofenac), a non-steroidal anti-inflammatory drug, greatly enhanced cardiac reprogramming in combination with Gata4, Mef2c, and Tbx5 (GMT) or GMT plus Hand2. Intriguingly, diclofenac promoted cardiac reprogramming in mouse postnatal and adult tail-tip fibroblasts (TTFs), but not in mouse embryonic fibroblasts (MEFs). Mechanistically, diclofenac enhanced cardiac reprogramming by inhibiting cyclooxygenase-2, prostaglandin E2/prostaglandin E receptor 4, cyclic AMP/protein kinase A, and interleukin 1β signaling and by silencing inflammatory and fibroblast programs, which were activated in postnatal and adult TTFs. Thus, anti-inflammation represents a new target for cardiac reprogramming associated with aging.

UR - http://www.scopus.com/inward/record.url?scp=85061770613&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061770613&partnerID=8YFLogxK

U2 - 10.1038/s41467-019-08626-y

DO - 10.1038/s41467-019-08626-y

M3 - Article

VL - 10

JO - Nature Communications

JF - Nature Communications

SN - 2041-1723

IS - 1

M1 - 674

ER -